Teladoc Health, Inc. provided revenue guidance for the year ending December 31, 2021. For the period, the company expects total revenue to be approximately $2,030 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.78 USD | -1.62% | -1.77% | -40.70% |
04-29 | Truist Securities Cuts Teladoc's Price Target to $15 From $17, Maintains Hold Rating | MT |
04-26 | UBS Adjusts Teladoc Price Target to $16 From $20, Maintains Neutral Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.70% | 2.17B | |
+26.46% | 2.42B | |
+115.18% | 703M | |
+24.80% | 538M | |
-61.74% | 169M | |
-42.45% | 72.48M |
- Stock Market
- Equities
- TDOC Stock
- News Teladoc Health, Inc.
- Teladoc Health, Inc. Provides Revenue Guidance for the Year Ending December 31, 2021